Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both ‘Buy’ and ‘Sell’ ratings on a range of pharmaceutical stocks.Here is a list of 6 pharma stocks on which UBS initiated coverage:
Shanghai Stock Exchange to run test after transaction delay
The Shanghai Stock Exchange will conduct tests on its auction and other platforms on Sunday following an unexplained transaction delay. The delay occurred during a
September 28, 2024